Special Reports

Follica starts with a market in search of a therapy Most biotech companies start with an interesting discovery technology or a drug development program and then go out in search of money to fund

Cash-hungry Portola aims at a blockbuster market Portola Pharmaceuticals isn't cheap to operate. When the South San Francisco-based developer announced it had completed raising $60 million in July,

Tetraphase readies its move into the clinic Tetraphase Pharmaceuticals' roots go back to Andrew Myers' laboratory at Harvard, where the chemist--who chairs the department of chemistry and chemical

Cytochroma plans to grow as it advances vitamin D work The business case for Cytochroma is built around the shortcomings of two lead therapies for hyperparathyroidism in patients with chronic kidney

Synosia relies on relationships to grow fast Back in 2005, Synosia Therapeutics was little more than a gleam in a venture capitalist's eye. Bradley Bolzon, an experienced biotech player and an

The first half of 2008 has drawn to a close, with deal-making still on a roll. In the first six months of this year, companies inked six pacts--both buyouts and licensing deals--that exceed the

VLST readies itself for a shift into the clinic Some biotechs thrive best outside the glare of public attention. And VLST, a fledgling graduate of Seattle's Accelerator Corp., has been using its

CoLucid helps define lean and mean in biotech A roster of new biotech companies has sprung up recently that relies on a virtual business model to keep costs down as they advance therapies to proof of

The 2007 rate of new biologic approvals was slow, with only a handful of drugs squeaking through FDA review. But the pace is set to pick up in 2008. According to IMS Health, these biologics could

Pharma development chief takes on role of biotech entrepreneur Over the past 20 years, Glenn Gormley, M.D., Ph.D., rose to a high altitude in the world of big pharma drug development. There were

By Maureen Martino and Tracy Staton It's never too early to identify trends, and what better place to look than the FDA? The environment at the world's premier regulatory agency can have a

by Tracy Staton and Maureen Martino Few statistics are as hotly debated as CEO pay reports. Investors, analysts, and the just plain curious all want to know how much the head honcho makes--and how

When we set out last week to identify the best-performing pharma stocks of 2007, we could resist scrolling to the bottom of the spreadsheet to

When it comes to picking stocks, prediction may be murky, but hindsight is crystal clear. We looked at every company in the Wall Street Journal's pharma sector (plus a few others of our own

Take a look at FiercePharma's 2007 year-end round-up and our predictions for the year ahead.   2007 pharma industry trends: 1.

Since FiercePharma was launched in August we’ve published hundreds of articles, but there are some that are clear favorites with our readers. Check out this list of our most-read articles in 2007

2007 was a year of high-profile drug safety warnings. Check out this report for a look at the 10 biggest drugs--ranked by 2006 sales--that drew new, FDA-issued warnings or withdrawals. 

2007 has been a year of high-profile drug safety warnings. Check out this report for a look at the 10 biggest drugs with new, FDA-issued warnings or withdrawals this year. The drugs are ranked by

Count GlaxoSmithKline's Puerto Rican plant as an early Avandia casualty. The drug maker will close the factory in Cidra, Puerto Rico, and transfer production of the diabetes med (and its cousin